Ioversol Market in China 2018-2022 - Jiangsu Hengrui Exceeded 90% Market Shares in 2017

DUBLIN, July 10, 2018 /PRNewswire/ --

The "Investigation Report on Chinese Ioversol Market, 2018-2022" report has been added to ResearchAndMarkets.com's offering.

Contract media are chemical products that are injected into or taken by human tissues or organs to improve image observation. The global contrast media market is growing continuously with higher demand for medical exam accuracy and increasing popularity of angiography.

Ioversol is a new-type non-ionic contrast agent mainly used in contrast-enhanced vascular imaging, featured by high contract density, avirulence, high tolerance and few side effects. After Ioversol is injected to blood vessels, the high proportion of iodine can cause x-ray attenuation and clearly shows the blood vessels till Ioversol is diluted.

Contrast media are among the most common drugs in interventional radiology practice. They are mainly used to show blood vessels and coeloms. With large growth momentum and potential, the applications of contrast media has gradually extended from x-ray photography/CT scan imaging to diagnoses and examinations such as ultrasonography and magnetic resonance angiography. Ioversol has been widely used in China. As the number of the diagnosed continues to rise, the Ioversol market will continue to grow in China.

With China's growing demand for Ioversol, the sales value exceeded CNY 400 million in 2017. According to research Jiangsu Hengrui, Liebel-Flarsheim and Mallinckrodt accounted for the major shares of the Chinese Ioversol market. By sales value, the market share of Jiangsu Hengrui exceeded 90% in 2017.

Key Topics Covered

1 Relevant Concepts of Ioversol
1.1 Indications
1.2 Development History of Ioversol in China
1.3 Production Permit of Ioversol in China

2 Investigation on Sales of Ioversol in China, 2013-2017
2.1 Sales Value of Ioversol in China
2.1.1 Overall Sales Value
2.1.2 Sales Value in Different Regions
2.2 Sales Volume of Ioversol in China
2.2.1 Overall Sales Volume
2.2.2 Sales Volume in Different Regions
2.3 Sales of Ioversol in Different Dosage Forms in China
2.3.1 Market Share of Ioversol in Different Dosage Forms by Sales Value
2.3.2 Market Share of Ioversol in Different Dosage Forms by Sales Volume

3 Investigation on Market Share of Major Ioversol Manufacturers in China, 2013-2017
3.1 Analysis on Market Competition of Ioversol in China, 2013-2017
3.1.1 Major Manufacturers
3.1.2 Market Share by Sales Value
3.1.3 Market Share by Sales Volume
3.2 Jiangsu Hengrui Medicine Co., Ltd.
3.2.1 Profile of Jiangsu Hengrui Medicine Co., Ltd.
3.2.2 Sales of Jiangsu Hengrui's Ioversol
3.2.3 Sales Price of Jiangsu Hengrui's Ioversol
3.3 Liebel-Flarsheim
3.4 Mallinckrodt

4 Prospects of Chinese Ioversol Market, 2018-2022
4.1 Forecast on Market Size
4.2 Forecast on Competition Pattern

Selected Charts
Chart Production Permit of Ioversol in China
Chart Sales of Ioversol in China
Chart Sales Value of Ioversol in China, 2007-2017
Chart Sales Value of Ioversol in Parts of China, 2013-2017
Chart Sales Volume of Ioversol in China, 2007-2017
Chart Sales Volume of Ioversol in Parts of China, 2013-2017
Chart Market Share and Sales Value of Jiangsu Hengrui's Ioversol in China, 2013-2017
Chart Market Share and Sales Value of Liebel-Flarsheim's Ioversol in China, 2013-2017
Chart Market Share and Sales Value of Mallinckrodt's Ioversol in China, 2013-2017
Chart Sales Value and Market Share of Ioversol Injections in China, 2013-2017
Chart Prices of Jiangsu Hengrui's Ioversol in Several Chinese Cities, 2017-2018
Chart Prices of Mallinckrodt's Ioversol in Several Chinese Cities, 2017-2018
Chart Forecast on Ioversol's Sales in China, 2018-2022

For more information about this report visit https://www.researchandmarkets.com/research/j77m4w/ioversol_market?w=5

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com   

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/ioversol-market-in-china-2018-2022---jiangsu-hengrui-exceeded-90-market-shares-in-2017-300678435.html

SOURCE Research and Markets